Artal Group S.A. Iovance Biotherapeutics, Inc. Transaction History

Artal Group S.A.

$1.58 Billion
Q2 2024

A detailed history of Artal Group S.A. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 1,011,500 shares of IOVA stock, worth $9.72 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

1,011,500

Holding current value

$9.72 Million

% of portfolio

0.51%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.78 - $14.19 $7.87 Million - $14.4 Million	1,011,500 New	1,011,500 $8.11 Million
Q2 2021 Aug 13, 2021	SELL	$16.33 - $33.07 $6.53 Million - $13.2 Million	-400,000 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$27.75 - $36.3 $2.78 Million - $3.63 Million	-100,000 Reduced 20.0%	400,000 $13.2 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $6.8 Million - $10.3 Million	-250,000 Reduced 33.33%	500,000 $13.7 Million
Q1 2020 May 14, 2020	BUY	$19.54 - $38.85 $4.89 Million - $9.71 Million	250,000 Added 50.0%	750,000 $22.5 Million
Q4 2019 Feb 13, 2020	SELL	$17.95 - $29.41 $3.59 Million - $5.88 Million	-200,000 Reduced 28.57%	500,000 $13.8 Million
Q2 2019 Aug 09, 2019	BUY	$9.78 - $24.52 $1.96 Million - $4.9 Million	200,000 Added 40.0%	700,000 $17.2 Million
Q4 2018 Feb 11, 2019	SELL	$7.51 - $11.93 $1.5 Million - $2.39 Million	-200,000 Reduced 28.57%	500,000 $4.43 Million
Q2 2018 Aug 10, 2018	BUY	$12.45 - $16.95 $2.99 Million - $4.07 Million	240,000 Added 52.17%	700,000 $8.96 Million
Q1 2018 May 10, 2018	BUY	$8.1 - $19.5 $3.73 Million - $8.97 Million	460,000 New	460,000 $7.77 Million

Others Institutions Holding IOVA

# of Institutions

323

Shares Held

239M

Call Options Held

1.27M

Put Options Held

1.68M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.52B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account